Press Releases & Announcements

ACTG ADDS NEW AGENT TO ACTIV-2 TRIAL INVESTIGATING EARLY COVID-19 TREATMENTS

Jan 05, 2021

NIH RE-FUNDS ACTG FOR THE NEXT SEVEN YEARS

Dec 09, 2020

NIH RE-FUNDS ACTG FOR THE NEXT SEVEN YEARS

Nov 30, 2020

2020 ACTG AWARDS

Nov 24, 2020

ACTG PRESENTS DATA SHOWING MINIMAL MONITORING APPROACH TO HEPATITIS C TREATMENT IS SAFE AND SUCCESSFUL AT AASLD’S 2020 LIVER MEETING

Nov 16, 2020

ACTG PRESENTS DATA SHOWING MINIMAL MONITORING APPROACH TO HEPATITIS C TREATMENT IS SAFE AND SUCCESSFUL AT AASLD’S 2020 LIVER MEETING

Nov 16, 2020

LANDMARK TRIAL DEMONSTRATES EFFECTIVENSS OF SHORTENED TB TREATMENT

Nov 05, 2020

ACTG REPRIEVE CHOSEN FOR VIIV GRANT

Jul 01, 2020

AN UPDATE ON A5395

Jun 23, 2020

A MESSAGE FROM LEADERSHIP

Jun 02, 2020

LONG-ACTING INJECTABLE CABOTEGRAVIR IS HIGHLY EFFECTIVE FOR THE PREVENTION OF HIV INFECTION IN CISGENDER MEN AND TRANSGENDER WOMEN WHO HAVE SEX WITH MEN

May 18, 2020

ACTG LAUNCHES CLINICAL TRIAL TESTING TREATMENT FOR COVID-19

May 14, 2020